ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

apremilast

Also written as “Apremilast”, “Apremilast 20mg” and “Apremilast 30mg”.

Its studies are mostly in Psoriasis · Arthritis, Psoriatic · Behcet Syndrome · Arthritis, Juvenile · COVID-19, led by 3 companies.

Drug pageApremilast: every studyAll 117 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Apr 3, 201548 company-led studies, 4 open or runningNext primary completion: Jan 10, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Amgenits history only464 open or runningphase 4since Apr 3, 2015Apr 2, 2007Jan 10, 2027phase 1 · NCT07908641
Boehringer Ingelheim10 open or runningphase 1since Mar 22, 2021Mar 22, 2021none ahead
Humanis Saglık Anonim Sirketiits history only10 open or runningphase 3since Oct 10, 2023Oct 10, 2023none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Boehringer Ingelheim only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 22, 2021First study: phase 1 study in HealthyFirst studyNCT04811573 · 20 enrolled · Germany

TargetBeta

“Phosphodiesterase 4 inhibitor”ChEMBL 37, by rule

Other programs on the same 4 targets

ProgramCompanyFurthest phaseStudies
RoflumilastruleAstraZenecaphase 461
ensifentrineruleMerckphase 317
difamilastruleOtsukaphase 316
tanimilastruleChiesi Farmaceuticiphase 315

Studies

The one study Boehringer Ingelheim leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04811573Healthy · Germany1TerminatedAug 18, 202120

How it is read

Names in the registry

  • “Apremilast”, 31 entries
  • “Apremilast 20mg”, 6 entries
  • “Apremilast 30mg”, 5 entries
  • “Apremilast (CC-10004)”, 3 entries
  • “Apremilast 30 mg”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.